Amendment: SEC Form SC 13G/A filed by Lyell Immunopharma Inc.
$LYEL
Biotechnology: Pharmaceutical Preparations
Health Care
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/30/2024 | $6.00 → $1.00 | Buy → Underperform | BofA Securities |
| 6/27/2024 | $6.00 → $1.00 | Buy → Neutral | H.C. Wainwright |
| 8/28/2023 | $15.00 → $5.00 | Overweight → Neutral | JP Morgan |
| 11/14/2022 | $15.00 → $7.00 | Overweight → Equal-Weight | Morgan Stanley |
| 11/11/2022 | $13.00 → $7.00 | Buy → Neutral | Goldman |
| 10/17/2022 | $12.00 | Buy | H.C. Wainwright |
| 1/6/2022 | $25.00 → $20.00 | Overweight | Morgan Stanley |
| 7/12/2021 | $25.00 | Buy | BofA Securities |
SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, announced today that members of its senior management team will present and participate in the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11th at 10:00 am ET. A live webcast of the presentation can be accessed through the Investors section of the Company's website at www.lyell.com. Following the live presentation, a replay of the webcast will be available on the Company's website following the presentation date. About Lyell Immunopharma, Inc. Ly
Presenting new clinical data from Phase 1/2 multi-center clinical trial of LYL314, a next-generation dual‑targeting CD19/CD20 CAR T-cell product candidate for the treatment of relapsed and/or refractory large B‑cell lymphoma at the 18th International Conference on Malignant Lymphoma.Received Regenerative Medicine Advanced Therapy (RMAT) designation from the United States Food and Drug Administration (FDA) for LYL314 for the treatment of relapsed and/or refractory diffuse large B-cell lymphoma in the third- or later-line setting.LYL314 clinical supply now manufactured at Lyell's LyFE Manufacturing Center™, following successful technology transfer and clearance by the FDA of an Investigational
SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced that an abstract highlighting new clinical data from the Phase 1/2 trial of LYL314 (formerly IMPT-314) in large B-cell lymphoma will be presented as an oral presentation at the International Conference on Malignant Lymphoma (ICML) 2025 taking place in Lugano, Switzerland June 17-21, 2025. LYL314 is a dual-targeting CD19/CD20 chimeric antigen receptor (CAR) T-cell product candidate in development for patients with aggressive large B-cell lymphoma. LYL314 has recei
Strengthens Lyell's clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidateData from ImmPACT's multi-center Phase 1-2 clinical trial of IMPT-314 in patients with large B-cell lymphoma treated in the 3rd line CAR-naïve setting to be presented at a major medical conference later this year; initiation of a pivotal trial for IMPT-314 expected in 2025Lyell has prioritized its pipeline to focus on next-generation CAR T-cell therapies, including IMPT-314 and LYL119, and is discontinuing development of LYL797, LYL845 and earlier-stage TIL programsCash runway following the close of the transaction is expected to fund operations into 2027, through impor
Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date (150 x 106 CAR T cells)First demonstration that CAR T cells enhanced with anti-exhaustion technology can both expand and infiltrate into solid tumorsNo significant safety signal related to LYL797 observed in patients without lung involvement; treatable pneumonitis observed in patients with lung metastatic disease; dose escalation continues in separate cohortsExpanding development into new tumor types including ROR1+ relapsed/refractory platinum-resistant ovarian cancer, endometrial cancer, multiple
BofA Securities downgraded Lyell Immunopharma from Buy to Underperform and set a new price target of $1.00 from $6.00 previously
H.C. Wainwright downgraded Lyell Immunopharma from Buy to Neutral and set a new price target of $1.00 from $6.00 previously
JP Morgan downgraded Lyell Immunopharma from Overweight to Neutral and set a new price target of $5.00 from $15.00 previously
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)
8-K - Lyell Immunopharma, Inc. (0001806952) (Filer)
SCHEDULE 13G/A - Lyell Immunopharma, Inc. (0001806952) (Subject)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
4 - Lyell Immunopharma, Inc. (0001806952) (Issuer)
SC 13G/A - Lyell Immunopharma, Inc. (0001806952) (Subject)
SC 13G/A - Lyell Immunopharma, Inc. (0001806952) (Subject)
SC 13G - Lyell Immunopharma, Inc. (0001806952) (Subject)
Cash, cash equivalents and marketable securities of $632.7 million as of June 30, 2023 support advancing multiple product candidates through key clinical milestonesRemain on track for initial clinical data from two lead product candidates in 2024Further strengthened executive leadership with appointment of Matt Lang, J.D., as Chief Business Officer SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today reported financial results and business highlights for the second quarter ended June 30, 2023. "Lyell continues
SOUTH SAN FRANCISCO, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that Matthew Lang, J.D. has joined the executive management team as Chief Business Officer. In this newly created role, Mr. Lang will serve on Lyell's executive committee and will be responsible for Lyell's legal, compliance, human resources, alliance management and early commercialization teams. He will also serve as Lyell's Chief Legal Officer and Corporate Secretary. "Matt is an experienced company builder who has successfully led growth in compl
SOUTH SAN FRANCISCO, Calif., Dec. 15, 2022 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (NASDAQ:LYEL), a clinical‑stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors, announced that Lynn Seely, MD, a member of the company's board and former president and chief executive officer (CEO) of Myovant Sciences, has been named Lyell's president & CEO effective today. Dr. Seely succeeds Ms. Liz Homans following a four-year tenure as president and then CEO. Ms. Homans will remain a consultant to the company through June 2024. Dr. Seely has extensive biopharmaceutical leadership experience with a track record of success building companies